FDA Grants New Indication for HydroMid® and HydroPICC® Catheters
Access Vascular, Inc. (AVI), a prominent player in advanced vascular access solutions, has announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for its innovative catheter lines, including the single-lumen MIMIX® HydroMid® and both single- and dual-lumen HydroPICC® catheters. The updated labeling now highlights the unique hydrogel material used in these devices, which exhibits anti-thrombogenic properties aimed at minimizing thrombus formation on catheter surfaces. This advancement is significant for healthcare providers looking to enhance patient safety and care effectiveness.
CEO Highlights Technological Advancements
During the announcement, James Biggins, the CEO of Access Vascular, remarked on the importance of these catheters in the realm of vascular access technology. He explained that the MIMIX® HydroMid® and HydroPICC® catheters utilize proprietary MIMIX® Technology to significantly decrease thrombus buildup without relying on drugs. This approach aligns with the company’s mission to support healthcare professionals in providing safer and more effective treatment options for patients.
How MIMIX® Technology Works
The MIMIX® Technology incorporated into these catheters is characterized by a bulk hydrogel material that forms a barrier at the molecular level on both the inner and outer surfaces of the catheters. In vitro studies have indicated that this barrier effectively reduces thrombus accumulation and the risk of occlusion. However, it is important to note that clinical impacts in human trials have yet to be evaluated, and these devices are not meant for treating existing vein thrombosis.
These catheters stand out in the market as they are the only FDA-cleared peripherally inserted central catheters (PICCs) and midline catheters with anti-thrombogenic indications that do not employ drug elution. By avoiding drug coatings, AVI’s products mitigate the potential risks associated with drug treatments, such as allergic reactions and the serious condition known as heparin-induced thrombocytopenia/thrombosis.
Commitment to Innovation in Vascular Access
Access Vascular is dedicated to advancing the field of vascular access care, and this FDA clearance marks a significant milestone in its ongoing efforts. The company, headquartered in Billerica, Massachusetts, specializes in developing and commercializing FDA-cleared medical devices that incorporate its innovative MIMIX® Technology, aimed at improving patient outcomes. For more detailed information on their products and initiatives, interested parties can visit their official website or find them on LinkedIn.
As the healthcare landscape continues to evolve, Access Vascular’s advancements in catheter technology represent a crucial step forward in enhancing patient safety and clinical efficiency in vascular access procedures.
Related
